Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Fibrogen Inc (FGEN) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Fibrogen Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 921299.
Total stock buying since 2015: $1,558,665.
Total stock sales since 2015: $220,602,753.
Total stock option exercises since 2015: $24,738,459.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 468,567 | $275,139 | 0 | $0 | 0 | $0 |
| 2024 | 50,000 | $95,450 | 0 | $0 | 0 | $0 |
| 2023 | 0 | $0 | 219,134 | $4,071,990 | 0 | $0 |
| 2022 | 0 | $0 | 6,943 | $107,123 | 0 | $0 |
| 2021 | 3,100 | $35,743 | 49,099 | $1,598,270 | 41,999 | $522,130 |
| 2020 | 27,800 | $988,883 | 146,666 | $5,897,563 | 161,886 | $3,059,897 |
| 2019 | 0 | $0 | 1,029,307 | $48,336,364 | 655,059 | $5,835,259 |
| 2018 | 0 | $0 | 1,359,531 | $73,772,269 | 808,272 | $6,849,677 |
| 2017 | 3,500 | $163,450 | 1,438,950 | $55,095,822 | 1,011,028 | $5,035,041 |
| 2016 | 0 | $0 | 880,582 | $17,119,568 | 456,814 | $1,757,502 |
| 2015 | 0 | $0 | 564,264 | $14,603,784 | 355,358 | $1,678,953 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-06 | 23,567 | $119,484 | 0 | $0 | 0 | $0 |
| 2025-03 | 445,000 | $155,655 | 0 | $0 | 0 | $0 |
| 2024-03 | 50,000 | $95,450 | 0 | $0 | 0 | $0 |
| 2023-09 | 0 | $0 | 2,000 | $2,060 | 0 | $0 |
| 2023-08 | 0 | $0 | 2,000 | $3,820 | 0 | $0 |
| 2023-07 | 0 | $0 | 3,880 | $10,644 | 0 | $0 |
| 2023-06 | 0 | $0 | 80,202 | $1,384,151 | 0 | $0 |
| 2023-04 | 0 | $0 | 17,641 | $332,742 | 0 | $0 |
| 2023-03 | 0 | $0 | 113,411 | $2,338,573 | 0 | $0 |
| 2022-12 | 0 | $0 | 6,943 | $107,123 | 0 | $0 |
| 2021-09 | 0 | $0 | 13,100 | $151,711 | 0 | $0 |
| 2021-08 | 3,100 | $35,743 | 0 | $0 | 0 | $0 |
| 2021-03 | 0 | $0 | 18,000 | $630,360 | 18,000 | $63,000 |
| 2021-02 | 0 | $0 | 6,000 | $315,720 | 6,000 | $171,900 |
| 2021-01 | 0 | $0 | 11,999 | $500,479 | 17,999 | $287,230 |
| 2020-12 | 0 | $0 | 12,419 | $517,787 | 6,001 | $112,188 |
| 2020-11 | 0 | $0 | 0 | $0 | 7,082 | $103,220 |
| 2020-09 | 0 | $0 | 31,425 | $1,554,174 | 25,004 | $552,354 |
| 2020-08 | 0 | $0 | 22,554 | $1,082,592 | 35,804 | $608,560 |
| 2020-07 | 0 | $0 | 3,351 | $141,914 | 0 | $0 |
| 2020-06 | 27,800 | $988,883 | 3,928 | $155,863 | 24,000 | $572,400 |
| 2020-03 | 0 | $0 | 38,489 | $941,280 | 29,495 | $321,635 |
| 2020-02 | 0 | $0 | 17,250 | $765,707 | 17,250 | $395,790 |
| 2020-01 | 0 | $0 | 17,250 | $738,246 | 17,250 | $393,750 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-06-30 | Schoeneck James A | Buy | 23,567 | 5.07 | 119,484 |
| 2025-03-24 | Wettig Thane (CEO) | Buy | 145,000 | .35 | 50,605 |
| 2025-03-21 | Schoeneck James A | Buy | 50,000 | .34 | 17,050 |
| 2025-03-20 | Schoeneck James A | Buy | 250,000 | .35 | 88,000 |
| 2024-03-07 | Wettig Thane (CEO) | Buy | 50,000 | 1.91 | 95,450 |
| 2023-09-01 | Henderson Jeffrey William (Director) | Sale | 2,000 | 1.03 | 2,060 |
| 2023-08-04 | Henderson Jeffrey William (Director) | Sale | 2,000 | 1.91 | 3,820 |
| 2023-07-11 | Henderson Jeffrey William (Director) | Sale | 2,000 | 2.69 | 5,380 |
| 2023-07-07 | Conterno Enrique A (Chief Executive Officer) | Sale | 1,880 | 2.80 | 5,264 |
| 2023-06-23 | Wettig Thane (Chief Commercial Officer) | Sale | 791 | 16.53 | 13,075 |
| 2023-06-14 | Chung Christine (SVP, China Operations) | Sale | 6,250 | 17.06 | 106,624 |
| 2023-06-13 | Chung Christine (SVP, China Operations) | Sale | 6,250 | 17.60 | 110,000 |
| 2023-06-09 | Cravatt Benjamin (Director) | Sale | 3,944 | 17.13 | 67,560 |
| 2023-06-09 | Blaug Suzanne (Director) | Sale | 8,520 | 17.12 | 145,862 |
| 2023-06-09 | Brennan Aoife (Director) | Sale | 4,733 | 17.13 | 81,076 |
| 2023-06-09 | Edwards Jeffrey L (Director) | Sale | 7,889 | 17.12 | 135,099 |
| 2023-06-08 | Ho Maykin (Director) | Sale | 8,520 | 17.23 | 146,842 |
| 2023-06-08 | Henderson Jeffrey William (Director) | Sale | 7,000 | 17.28 | 120,960 |
| 2023-06-07 | Graham Juan (Chief Financial Officer) | Sale | 1,785 | 16.99 | 30,334 |
| 2023-06-07 | Eisner Mark (EVP, Chief Medical Officer) | Sale | 2,042 | 17.04 | 34,791 |
| 2023-06-07 | Wettig Thane (Chief Commercial Officer) | Sale | 1,758 | 17.04 | 29,951 |
| 2023-06-07 | Chung Christine (SVP, China Operations) | Sale | 3,633 | 17.04 | 61,891 |
| 2023-06-07 | Conterno Enrique A (Chief Executive Officer) | Sale | 8,897 | 17.04 | 151,578 |
| 2023-06-07 | Schoeneck James A (Director) | Sale | 7,100 | 18.03 | 127,984 |
| 2023-06-02 | Eisner Mark (EVP, Chief Medical Officer) | Sale | 1,090 | 18.83 | 20,524 |
| 2023-04-10 | Conterno Enrique A (Chief Executive Officer) | Sale | 1,869 | 19.52 | 36,482 |
| 2023-04-04 | Eisner Mark (Chief Medical Officer) | Sale | 9,182 | 18.78 | 172,474 |
| 2023-04-04 | Chung Christine (SVP, China Operations) | Sale | 6,590 | 18.78 | 123,786 |
| 2023-03-23 | Wettig Thane (Chief Commercial Officer) | Sale | 905 | 18.71 | 16,932 |
| 2023-03-10 | Graham Juan (Chief Financial Officer) | Sale | 4,912 | 20.20 | 99,207 |
| 2023-03-10 | Eisner Mark (Chief Medical Officer) | Sale | 10,140 | 20.20 | 204,797 |
| 2023-03-10 | Wettig Thane (Chief Commercial Officer) | Sale | 7,669 | 20.20 | 154,890 |
| 2023-03-10 | Chung Christine (SVP, China Operations) | Sale | 7,606 | 20.20 | 153,618 |
| 2023-03-10 | Conterno Enrique A (Chief Executive Officer) | Sale | 31,589 | 20.20 | 638,003 |
| 2023-03-08 | Graham Juan (Chief Financial Officer) | Sale | 2,749 | 21.16 | 58,157 |
| 2023-03-08 | Eisner Mark (Chief Medical Officer) | Sale | 7,363 | 21.16 | 155,771 |
| 2023-03-08 | Wettig Thane (Chief Commercial Officer) | Sale | 6,265 | 21.16 | 132,542 |
| 2023-03-08 | Chung Christine (SVP, China Operations) | Sale | 8,354 | 21.16 | 176,737 |
| 2023-03-08 | Conterno Enrique A (Chief Executive Officer) | Sale | 24,672 | 21.16 | 521,960 |
| 2023-03-02 | Eisner Mark (Chief Medical Officer) | Sale | 1,187 | 21.87 | 25,959 |
| 2022-12-23 | Wettig Thane (Chief Commercial Officer) | Sale | 734 | 15.80 | 11,597 |
| 2022-12-12 | Graham Juan (Chief Financial Officer) | Sale | 1,407 | 14.50 | 20,401 |
| 2022-12-09 | Graham Juan (Chief Financial Officer) | Sale | 781 | 14.90 | 11,636 |
| 2022-12-08 | Wettig Thane (Chief Commercial Officer) | Sale | 382 | 15.79 | 6,031 |
| 2022-12-08 | Chung Christine (SVP, China Operations) | Sale | 1,096 | 15.79 | 17,305 |
| 2022-12-08 | Conterno Enrique A (Chief Executive Officer) | Sale | 2,543 | 15.79 | 40,153 |
| 2021-09-15 | Kearns Thomas F Jr (Director) | Sale | 13,100 | 11.58 | 151,711 |
| 2021-08-26 | Wettig Thane (Chief Commercial Officer) | Buy | 3,100 | 11.53 | 35,743 |
| 2021-03-11 | Kearns Thomas F Jr (Director) | Sale | 18,000 | 35.02 | 630,360 |
| 2021-03-11 | Kearns Thomas F Jr (Director) | Option Ex | 18,000 | 3.50 | 63,000 |
| 2021-02-17 | Kurkijarvi Kalevi (Director) | Sale | 6,000 | 52.62 | 315,720 |
| 2021-02-17 | Kurkijarvi Kalevi (Director) | Option Ex | 6,000 | 28.65 | 171,900 |
| 2021-01-19 | Kurkijarvi Kalevi (Director) | Sale | 6,000 | 43.38 | 260,280 |
| 2021-01-19 | Kurkijarvi Kalevi (Director) | Option Ex | 6,000 | 19.05 | 114,300 |
| 2021-01-14 | Kurkijarvi Kalevi (Director) | Sale | 5,999 | 40.04 | 240,199 |
| 2021-01-14 | Kurkijarvi Kalevi (Director) | Option Ex | 5,999 | 19.05 | 114,280 |
| 2021-01-04 | Schoeneck James A (Director) | Option Ex | 6,000 | 9.78 | 58,650 |
| 2020-12-28 | Kurkijarvi Kalevi (Director) | Sale | 6,001 | 40.77 | 244,630 |
| 2020-12-28 | Kurkijarvi Kalevi (Director) | Option Ex | 6,001 | 18.70 | 112,188 |
| 2020-12-16 | Yu K Peony (Chief Medical Officer) | Sale | 3,350 | 41.61 | 139,393 |
| 2020-12-15 | Cotroneo Pat (SVP, Finance and CFO) | Sale | 3,068 | 43.60 | 133,764 |
| 2020-11-17 | Kouchakji Elias (SVP, Clinical Dev, Drug Safety) | Option Ex | 7,082 | 14.57 | 103,220 |
| 2020-09-16 | Yu K Peony (Chief Medical Officer) | Sale | 3,351 | 44.01 | 147,477 |
| 2020-09-15 | Cotroneo Pat (SVP, Finance and CFO) | Sale | 3,070 | 43.63 | 133,944 |
| 2020-09-03 | Cotroneo Pat (SVP, Finance and CFO) | Sale | 15,004 | 50.91 | 763,853 |
| 2020-09-03 | Cotroneo Pat (SVP, Finance and CFO) | Option Ex | 15,004 | 24.82 | 372,354 |
| 2020-09-03 | Yu K Peony (Chief Medical Officer) | Sale | 10,000 | 50.89 | 508,900 |
| 2020-09-03 | Yu K Peony (Chief Medical Officer) | Option Ex | 10,000 | 18.00 | 180,000 |
| 2020-08-20 | Schoeneck James A (Director) | Option Ex | 6,000 | 5.95 | 35,700 |
| 2020-08-11 | Cotroneo Pat (SVP, Finance and CFO) | Option Ex | 7,250 | 18.70 | 135,538 |
| 2020-08-07 | Cotroneo Pat (SVP, Finance and CFO) | Sale | 22,554 | 48.00 | 1,082,592 |
| 2020-08-07 | Cotroneo Pat (SVP, Finance and CFO) | Option Ex | 22,554 | 19.39 | 437,322 |
| 2020-07-24 | Yu K Peony (Chief Medical Officer) | Sale | 3,351 | 42.35 | 141,914 |
| 2020-06-16 | Cotroneo Pat (SVP, Finance and CFO) | Sale | 3,928 | 39.68 | 155,863 |
| 2020-06-11 | Conterno Enrique A (Chief Executive Officer) | Buy | 19,800 | 35.28 | 698,603 |
| 2020-06-10 | Conterno Enrique A (Chief Executive Officer) | Buy | 8,000 | 36.28 | 290,280 |
| 2020-06-09 | Rosenkranz Roberto Pedro (Director) | Option Ex | 24,000 | 23.85 | 572,400 |
| 2020-03-19 | Chung Christine (SVP, China Operations) | Sale | 7,345 | 25.11 | 184,432 |
| 2020-03-19 | Chung Christine (SVP, China Operations) | Option Ex | 7,345 | 25.40 | 186,563 |
| 2020-03-19 | Kearns Thomas F Jr (Director) | Sale | 18,000 | 23.17 | 417,078 |
| 2020-03-19 | Kearns Thomas F Jr (Director) | Option Ex | 18,000 | 2.90 | 52,200 |
| 2020-03-18 | Chung Christine (SVP, China Operations) | Sale | 3,905 | 24.64 | 96,230 |
| 2020-03-18 | Chung Christine (SVP, China Operations) | Option Ex | 400 | 25.40 | 10,160 |
| 2020-03-16 | Cotroneo Pat (SVP, Finance and CFO) | Sale | 9,239 | 26.36 | 243,540 |
| 2020-03-16 | Yu K Peony (Chief Medical Officer) | Option Ex | 3,750 | 19.39 | 72,712 |
| 2020-02-12 | Chung Christine (SVP, China Operations) | Sale | 5,625 | 46.11 | 259,368 |
| 2020-02-12 | Chung Christine (SVP, China Operations) | Option Ex | 5,625 | 25.40 | 142,875 |
| 2020-02-11 | Chung Christine (SVP, China Operations) | Sale | 5,625 | 44.48 | 250,199 |
| 2020-02-11 | Chung Christine (SVP, China Operations) | Option Ex | 5,625 | 25.40 | 142,875 |
| 2020-02-10 | Kurkijarvi Kalevi (Director) | Sale | 6,000 | 42.69 | 256,140 |
| 2020-02-10 | Kurkijarvi Kalevi (Director) | Option Ex | 6,000 | 18.34 | 110,040 |
| 2020-01-07 | Chung Christine (SVP, China Operations) | Sale | 5,625 | 42.76 | 240,525 |
| 2020-01-07 | Chung Christine (SVP, China Operations) | Option Ex | 5,625 | 25.40 | 142,875 |
| 2020-01-06 | Chung Christine (SVP, China Operations) | Sale | 5,625 | 42.98 | 241,762 |
| 2020-01-06 | Chung Christine (SVP, China Operations) | Option Ex | 5,625 | 25.40 | 142,875 |
| 2020-01-06 | Kurkijarvi Kalevi (Director) | Sale | 6,000 | 42.66 | 255,959 |
| 2020-01-06 | Kurkijarvi Kalevi (Director) | Option Ex | 6,000 | 18.00 | 108,000 |
| 2019-12-20 | Cotroneo Pat (SVP, Finance and CFO) | Sale | 59,456 | 45.89 | 2,728,435 |
| 2019-12-20 | Cotroneo Pat (SVP, Finance and CFO) | Option Ex | 56,254 | 8.01 | 450,482 |
| 2019-12-17 | Chung Christine (SVP, China Operations) | Sale | 5,625 | 47.21 | 265,556 |
| 2019-12-17 | Chung Christine (SVP, China Operations) | Option Ex | 5,625 | 25.40 | 142,875 |
| 2019-12-16 | Chung Christine (SVP, China Operations) | Sale | 5,625 | 47.09 | 264,853 |
| 2019-12-16 | Chung Christine (SVP, China Operations) | Option Ex | 2,120 | 25.40 | 53,848 |
| 2019-12-16 | Yu K Peony (Chief Medical Officer) | Sale | 3,420 | 46.68 | 159,645 |
| 2019-12-09 | Kurkijarvi Kalevi (Director) | Sale | 6,000 | 47.50 | 285,000 |
| 2019-12-09 | Kurkijarvi Kalevi (Director) | Option Ex | 6,000 | 18.00 | 108,000 |
| 2019-12-04 | Yu K Peony (Chief Medical Officer) | Option Ex | 4,157 | 16.29 | 67,709 |
| 2019-11-14 | Chung Christine (SVP, China Operations) | Sale | 5,625 | 34.84 | 195,975 |
| 2019-11-14 | Chung Christine (SVP, China Operations) | Option Ex | 5,625 | 22.39 | 125,971 |
| 2019-11-13 | Chung Christine (SVP, China Operations) | Sale | 5,625 | 34.54 | 194,287 |
| 2019-11-13 | Chung Christine (SVP, China Operations) | Option Ex | 5,625 | 19.39 | 109,068 |
| 2019-11-08 | Cotroneo Pat (SVP, Finance and CFO) | Option Ex | 12,500 | 2.90 | 36,250 |
| 2019-11-07 | Kurkijarvi Kalevi (Director) | Sale | 6,000 | 38.47 | 230,790 |
| 2019-11-07 | Kurkijarvi Kalevi (Director) | Option Ex | 6,000 | 9.78 | 58,650 |
| 2019-10-09 | Chung Christine (SVP, China Operations) | Sale | 5,625 | 36.58 | 205,762 |
| 2019-10-09 | Chung Christine (SVP, China Operations) | Option Ex | 5,625 | 19.39 | 109,068 |
| 2019-10-08 | Chung Christine (SVP, China Operations) | Sale | 5,625 | 36.83 | 207,140 |
| 2019-10-08 | Chung Christine (SVP, China Operations) | Option Ex | 5,625 | 19.39 | 109,068 |
| 2019-10-07 | Kurkijarvi Kalevi (Director) | Sale | 6,000 | 36.73 | 220,379 |
| 2019-10-07 | Kurkijarvi Kalevi (Director) | Option Ex | 6,000 | 9.78 | 58,650 |
| 2019-09-20 | Chung Christine (SVP, China Operations) | Sale | 5,625 | 39.87 | 224,268 |
| 2019-09-20 | Chung Christine (SVP, China Operations) | Option Ex | 5,625 | 19.39 | 109,068 |
| 2019-09-19 | Chung Christine (SVP, China Operations) | Sale | 5,625 | 40.38 | 227,109 |
| 2019-09-19 | Chung Christine (SVP, China Operations) | Option Ex | 2,120 | 19.39 | 41,106 |
| 2019-09-17 | Cotroneo Pat (SVP, Finance and CFO) | Sale | 3,201 | 41.38 | 132,457 |
| 2019-09-16 | Yu K Peony (Chief Medical Officer) | Sale | 3,419 | 40.92 | 139,905 |
| 2019-09-09 | Kurkijarvi Kalevi (Director) | Sale | 6,000 | 41.28 | 247,709 |
| 2019-09-09 | Kurkijarvi Kalevi (Director) | Option Ex | 6,000 | 5.95 | 35,700 |
| 2019-08-23 | Chung Christine (SVP, China Operations) | Sale | 5,625 | 42.89 | 241,256 |
| 2019-08-23 | Chung Christine (SVP, China Operations) | Option Ex | 5,625 | 19.39 | 109,068 |
| 2019-08-22 | Chung Christine (SVP, China Operations) | Sale | 5,625 | 44.23 | 248,793 |
| 2019-08-22 | Chung Christine (SVP, China Operations) | Option Ex | 5,625 | 19.39 | 109,068 |
| 2019-08-22 | Neff Thomas B (Chief Executive Officer) | Sale | 19,818 | 44.10 | 873,973 |
| 2019-08-22 | Neff Thomas B (Chief Executive Officer) | Option Ex | 6,834 | 2.90 | 19,818 |
| 2019-08-21 | Neff Thomas B (Chief Executive Officer) | Sale | 19,818 | 44.80 | 887,846 |
| 2019-08-21 | Neff Thomas B (Chief Executive Officer) | Option Ex | 6,834 | 2.90 | 19,818 |
| 2019-08-13 | Neff Thomas B (Chief Executive Officer) | Sale | 39,636 | 45.75 | 1,813,346 |
| 2019-08-13 | Neff Thomas B (Chief Executive Officer) | Option Ex | 13,668 | 2.90 | 39,636 |
| 2019-08-12 | Neff Thomas B (Chief Executive Officer) | Sale | 39,636 | 45.32 | 1,796,302 |
| 2019-08-12 | Neff Thomas B (Chief Executive Officer) | Option Ex | 13,668 | 2.90 | 39,636 |
| 2019-08-05 | Kurkijarvi Kalevi (Director) | Sale | 6,000 | 45.22 | 271,320 |
| 2019-08-05 | Kurkijarvi Kalevi (Director) | Option Ex | 6,000 | 3.50 | 21,000 |
| 2019-07-25 | Neff Thomas B (Chief Executive Officer) | Sale | 19,818 | 47.32 | 937,787 |
| 2019-07-25 | Neff Thomas B (Chief Executive Officer) | Option Ex | 6,834 | 2.90 | 19,818 |
| 2019-07-24 | Neff Thomas B (Chief Executive Officer) | Sale | 19,818 | 46.55 | 922,626 |
| 2019-07-24 | Neff Thomas B (Chief Executive Officer) | Option Ex | 6,834 | 2.90 | 19,818 |
| 2019-07-11 | Chung Christine (SVP, China Operations) | Sale | 5,625 | 45.42 | 255,515 |
| 2019-07-11 | Chung Christine (SVP, China Operations) | Option Ex | 5,625 | 24.52 | 137,953 |
| 2019-07-11 | Neff Thomas B (Chief Executive Officer) | Sale | 19,818 | 45.30 | 897,695 |
| 2019-07-11 | Neff Thomas B (Chief Executive Officer) | Option Ex | 6,834 | 2.90 | 19,818 |
Insider trading activities including stock purchases, stock sales, and option exercises of FGEN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Fibrogen Inc (symbol FGEN, CIK number 921299) see the Securities and Exchange Commission (SEC) website.